<DOC>
	<DOCNO>NCT02656875</DOCNO>
	<brief_summary>Patients moderate severe pain cause medical condition surgery , require IV opioid therapy may enrol open label safety study . Patients treat TRV130 IV bolus , PCA ( patient-controlled analgesia ) administration , , determine investigator , duration exceed 14 day .</brief_summary>
	<brief_title>A Open-label Study Evaluate Safety TRV130 Patients With Acute Pain</brief_title>
	<detailed_description>The duration treatment patient determine clinical need parenteral opioid therapy . Eligible patient moderate severe pain cause medical condition surgery , require IV opioid therapy may enrol open label safety study . Patients treat TRV130 IV bolus , PCA administration , , determine investigator , duration exceed 14 day . The duration treatment patient determine clinical need parenteral opioid therapy . A follow-up assessment take place 2-3 day completion treatment phase .</detailed_description>
	<mesh_term>Acute Pain</mesh_term>
	<criteria>Inclusion Criteria include : Moderate severe acute pain parenteral opioid therapy warrant Able understand comply procedure study requirement , provide write informed consent study procedure . Exclusion Criteria include : Clinically significant medical , surgical , postsurgical , psychiatric substance abuse condition history condition would confound interpretation safety , tolerability , efficacy data study . Hemodynamic instability respiratory insufficiency . Advanced cancer palliative endoflife care . Another current painful condition ( acute pain parenteral opioid therapy warrant ) would confound interpretation safety , tolerability , efficacy data study . Clinically significant , immunemediated hypersensitivity reaction opioids .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>